Loading clinical trials...

UNKNOWNPHASE1

Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects

NCT02609711•Ahn-Gook Pharmaceuticals Co.,Ltd

View on ClinicalTrials.gov

Summary

primary object : Evaluate pharmacokinetic drug-drug interaction of Candesartan and Atorvastatin

Eligibility

Age

19 - 45 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Adult healthy males 20 to 45 years at screening.
•BMI 18-29 kg/m2

Exclusion Criteria

•History of cardiovascular, respiratory, hepatic, renal, neuropsychiatric, endocrine, hematologic disease
•Hypersensitivity reactions to drugs or significant hypersensitivity reactions in the history of Candesartan and Atorvastatin
•Hypotension (DBP ≤ 100 mmHg or SBP ≤ 95mmHg) and hypertension (SBP ≥ 150 mmHg or DBP ≥ 95 mmHg)
•Gastrointestinal disease affected the absorption of medications
•Genetic disease of Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
•AST or ALT \> 2 x normal range
•Total bilirubin \> 2.0 mg/dl
•CK \> 2 x normal range
•eGFR \< 60 mL/min/1.73m2
•Subject who have drunken habitually (alcohol more than 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) or who are unable to quit drinking during this study
+9 more criteria

Locations (1)

Inha Univ. Hospital

Incheon, Incheon, South Korea

Key Dates

Start Date

November 1, 2015

Primary Completion Date

March 1, 2016

Last Updated

November 20, 2015

Enrollment

ESTIMATED participants

Conditions

Healthy Male Subjects

Interventions

Candesartan cilexetil

DRUG

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

NCT05245669

Healthy Male Subjects

View study

COMPLETEDPHASE1

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

NCT06111196

Healthy Male Subjects

View study

COMPLETEDPHASE1/PHASE2

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 20, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects

Inclusion Criteria

Exclusion Criteria

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Mass Balance and Biotransformation Study of [14C]DBPR108 in Human